West delivers innovative solutions to improve the safe delivery of pharmaceutical, health care and personal care products and is the world’s premier manufacturer of components and systems for injectable drug delivery. We serve the world’s leading pharmaceutical and biopharmaceutical companies.
Pharmaceutical, biopharmaceutical and medical device companies around the world rely on West Pharmaceutical Services, Inc. for standard-setting systems and device components for parenterally administered medicines.
West applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer health care products.
West Analytical Services applies decades of pharmaceutical industry drug product testing, development and packaging expertise to assist customers through the complex laboratory analysis associated with meeting drug product, stability, container closure and packaging regulatory guidelines.
West’s professionals provide expertise to customers from early product development through full production. Our expertise helps mitigate risk, implement world-class production technologies and comply with global regulatory requirements. West has made substantial investments in products, processes and plants that will add value for customers now and in the future.
The Tech Group, a West company, is a global leader in injection molding offering contract manufacturing solutions for pharmaceutical delivery systems, medical devices and personal care and consumer products.
Medimop Medical Projects Ltd., a West company, is a leader in the world market for transfer, mixing and administration systems for injectable pharmaceuticals.
Founded in 1923 with global headquarters in Lionville, Pennsylvania, West has a presence in North America, South America, Asia/Pacific, Middle East and Europe and 6,300 employees worldwide. The West name means assured top quality to the leaders of the global pharmaceutical industry. Customers rely on West’s packaging systems and components for safety, efficiency, reliability and leading-edge technologies that improve drug administration. Shares of West’s common stock are traded on the New York Stock Exchange under the symbol WST.
Company Growth (employees)
West Pharmaceutical Services was founded in 1923 and is headquartered in Exton, US
West Pharmaceutical Services Office Locations
West Pharmaceutical Services has an office in Exton
Exton, US (HQ)
530 Herman O. W Dr
West Pharmaceutical Services Data and Metrics
West Pharmaceutical Services Financial Metrics
West Pharmaceutical Services's revenue was reported to be $387.7 m in Q1, 2017
USD
Revenue (Q1, 2017) | 387.7 m |
Net income (Q1, 2017) | 60.9 m |
EBIT (Q1, 2017) | 61.3 m |
Market capitalization (17-Aug-2017) | 6.5 b |
Cash (31-Mar-2017) | 169.4 m |
West Pharmaceutical Services's current market capitalization is $6.5 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 1.4 b | 1.4 b | 1.4 b | 1.5 b |
Revenue growth, % | 4% | (2%) | 8% | |
Gross profit | 434.7 m | 447.8 m | 455.8 m | |
Gross profit Margin, % | 32% | 32% | 33% | |
R&D expense | 36.8 m | |||
General and administrative expense | 239.8 m | |||
Operating expense total | 276.6 m | |||
EBIT | 162.4 m | 182 m | 128.6 m | 196.8 m |
EBIT margin, % | 12% | 13% | 9% | 13% |
Interest expense | 17 m | 16.5 m | 14.1 m | 8.1 m |
Interest income | 1.9 m | 3.5 m | 1.6 m | 1.1 m |
Pre tax profit | 147.1 m | 169 m | 116.1 m | 189.8 m |
Income tax expense | 40.2 m | 47.2 m | 26.3 m | 54.4 m |
Net Income | 112.3 m | 127.1 m | 95.6 m | 143.6 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 368.9 m | 355.9 m | 335.9 m | 359.7 m | 344.5 m | 362.1 m | 388 m | 376.7 m | 387.7 m |
R&D expense | 9.9 m | 9.6 m | 7.5 m | 8.1 m | 8.5 m | 9.4 m | 8.8 m | 9 m | 10.3 m |
General and administrative expense | 57.5 m | 56 m | 55.2 m | 60.8 m | 54.6 m | 58.1 m | 62.5 m | 58.3 m | 61.6 m |
Operating expense total | 67.4 m | 65.6 m | 62.7 m | 68.9 m | 63.1 m | 67.5 m | 71.3 m | 67.3 m | 71.9 m |
EBIT | 54.1 m | 44 m | 47.8 m | 39.1 m | 30 m | 61.2 m | 51.3 m | 61.3 m | |
EBIT margin, % | 15% | 12% | 14% | 11% | 8% | 16% | 14% | 16% | |
Interest expense | 4.2 m | 4.5 m | 4.1 m | 3.4 m | 3.7 m | 2.5 m | 2 m | 2.2 m | 2.1 m |
Interest income | 500 k | 1.8 m | 400 k | 400 k | 500 k | 300 k | 300 k | 200 k | 300 k |
Pre tax profit | 50.4 m | 41.3 m | 44.1 m | 36.1 m | (6.7 m) | 27.8 m | 59.5 m | 49.3 m | 59.5 m |
Income tax expense | 14 m | 11.7 m | 12.5 m | 9.2 m | (6.6 m) | 6.9 m | 17 m | 14.4 m | 2.2 m |
Net Income | 37.6 m | 31 m | 32.9 m | 27.8 m | 1.5 m | 22.1 m | 44.7 m | 37.6 m | 60.9 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 230 m | 255.3 m | 274.6 m | 203 m |
Accounts Receivable | 185.7 m | 179 m | 181.4 m | 200.5 m |
Inventories | 176.9 m | 181.5 m | 181.1 m | 199.3 m |
Current Assets | 650.7 m | 659.3 m | 673.7 m | 641.9 m |
PP&E | 711.7 m | 705.8 m | 721 m | 778.3 m |
Goodwill | 114.2 m | 108.6 m | 104.6 m | 103 m |
Total Assets | 1.7 b | 1.7 b | 1.7 b | 1.7 b |
Accounts Payable | 108 m | 103.1 m | 119.8 m | 122 m |
Total Debt | 226.2 m | |||
Current Liabilities | 236.9 m | 252.5 m | 314.3 m | 241 m |
Total Liabilities | 599.2 m | |||
Additional Paid-in Capital | 120 m | 160.2 m | 207.8 m | 260.4 m |
Retained Earnings | 805 m | 902.2 m | 964.6 m | 1.1 b |
Total Equity | 906.4 m | 956.9 m | 1 b | 1.1 b |
Debt to Equity Ratio | 0.2 x | |||
Debt to Assets Ratio | 0.1 x | |||
Financial Leverage | 1.8 x | 1.7 x | 1.7 x | 1.5 x |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 226.7 m | 246.8 m | 207.1 m | 252 m | 256.8 m | 178.1 m | 202.7 m | 205.9 m | 169.4 m |
Accounts Receivable | 209.6 m | 195.9 m | 189.5 m | 198.8 m | 194.6 m | 209.6 m | 219 m | 209.5 m | 224.8 m |
Inventories | 187.9 m | 185.7 m | 183.4 m | 187.2 m | 187.7 m | 194.1 m | 197.7 m | 201.1 m | 212.3 m |
Current Assets | 685.4 m | 679.5 m | 625.1 m | 679.9 m | 680.9 m | 630.7 m | 659.2 m | 658.1 m | 652.6 m |
PP&E | 709.2 m | 694.8 m | 675.8 m | 685.4 m | 689.5 m | 732.5 m | 741.2 m | 772.7 m | 782.8 m |
Goodwill | 114 m | 110.4 m | 104.4 m | 105.3 m | 105.7 m | 105.7 m | 104.9 m | 105.2 m | 103.5 m |
Total Assets | 1.7 b | 1.7 b | 1.6 b | 1.7 b | 1.7 b | 1.7 b | 1.7 b | 1.7 b | 1.7 b |
Accounts Payable | 94.5 m | 91.4 m | 88.5 m | 91.4 m | 93.6 m | 97.5 m | 107.3 m | 99 m | 106.1 m |
Current Liabilities | 221.2 m | 242.5 m | 296.6 m | 313.7 m | 299.9 m | 241.1 m | 239.4 m | 236.8 m | 256.5 m |
Additional Paid-in Capital | 138.2 m | 149.1 m | 170.4 m | 188.6 m | 195.8 m | 238.5 m | 240.6 m | 247.6 m | 276 m |
Retained Earnings | 855.5 m | 878.7 m | 927.2 m | 947 m | 939.9 m | 978 m | 1 b | 1 b | 1.1 b |
Total Equity | 972.6 m | 970.1 m | 941.1 m | 989.4 m | 995.3 m | 1.1 b | 1.1 b | 1.1 b | 1.2 b |
Financial Leverage | 1.8 x | 1.7 x | 1.7 x | 1.7 x | 1.7 x | 1.6 x | 1.5 x | 1.5 x | 1.5 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 112.3 m | 127.1 m | 95.6 m | 143.6 m |
Depreciation and Amortization | 81 m | 84.8 m | 86.1 m | 88.1 m |
Accounts Receivable | (9.1 m) | (6.3 m) | (14 m) | (23.3 m) |
Inventories | (14 m) | (16 m) | (11 m) | (21.2 m) |
Accounts Payable | 4.6 m | (3.5 m) | 17.2 m | 6.1 m |
Cash From Operating Activities | 220.5 m | 182.9 m | 212.4 m | 219.4 m |
Capital Expenditures | (151.9 m) | (111.9 m) | (131.6 m) | (170.2 m) |
Cash From Investing Activities | (149.9 m) | (104 m) | (129.5 m) | (175.8 m) |
Long-term Borrowings | (30.5 m) | (2.3 m) | (27.4 m) | (69.8 m) |
Dividends Paid | (26.8 m) | (29.1 m) | (32.4 m) | (35.8 m) |
Cash From Financing Activities | (5.1 m) | (30.8 m) | (41.5 m) | (113.9 m) |
Interest Paid | 16.9 m | 16.7 m | 14.7 m | 8.6 m |
Free Cash Flow | 372.4 m | 294.8 m | 344 m | 49.2 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 37.6 m | 31 m | 32.9 m | 27.8 m | 1.5 m | 22.1 m | 44.7 m | 37.6 m | 60.9 m |
Accounts Receivable | 198.8 m | 194.6 m | 209.6 m | 219 m | 209.5 m | 224.8 m | |||
Inventories | 187.2 m | 187.7 m | 194.1 m | 197.7 m | 201.1 m | 212.3 m | |||
Accounts Payable | 91.4 m | 93.6 m | 97.5 m | 107.3 m | 99 m | 106.1 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 53.1 k |
Financial Leverage | 1.5 x |
West Pharmaceutical Services Market Value History
West Pharmaceutical Services Median Salaries
Source: 17 public H-1B filings from West Pharmaceutical Services
